His Labs Were Normal. The Fatigue Wasn't.

He didn't come in for fatigue. He came in for tendons — we were already running BPC-157 and TB-4 for joint and tissue repair. The fatigue surfaced as an aside: workouts feel less productive, recovery has lengthened. Something's off, but nothing obviously wrong.

So we ran the differential.

Total testosterone, free testosterone, bioavailable testosterone — all normal. No overt hypogonadism. Then we looked for the mid-40s trap: occult hypogonadism, the pattern where total T looks fine but visceral adiposity, low SHBG, and aromatized estradiol unmask functional insufficiency. None of those markers fit here. Minimal subcutaneous adiposity, normal SHBG, no estradiol elevation, no prediabetes. The classic picture didn't apply.

CRP unremarkable. No obesity-driven inflammatory signal. HbA1c excellent, fasting insulin in range, lipids fine. Thyroid screened.

Every panel came back reassuring in the way folks hate — because the body isn't agreeing.

That's when the question shifts. Not what's wrong with the system, but is the system asking the cell to do something the cell can't keep up with anymore?

This case is a composite drawn from three current KEH patients. The clinical specifics — labs, decision logic, what we tried — are real. The identifying details are not. We've done it this way because the pattern matters more than any one patient.

A man in his mid-40s. Lean, training 3–4 times a week, dialed for years. Body comp where he wants it. Sleep fine. Diet solid. Nothing obviously broken.

The complaint is recovery. Workouts feel less productive than the effort going in. Soreness lingers a day or two longer than it used to. He's putting in the same sessions — intensity, volume, frequency — and getting a return that doesn't match. The gap between effort and result has been quietly opening for the past couple of years. The calendar has been answering this question.

Running the differential

This kind of presentation has a standard workup. We ran it.

Overt hypogonadism. Total testosterone, free testosterone, bioavailable testosterone — all normal. The symptom cluster that goes with low T (libido decline, mood shift, morning erections gone) — not present. Nothing points here. Would have tipped: low total T, blunted LH/FSH response, the full picture of HPTA suppression.

Occult hypogonadism. This is the mid-40s male trap we look for explicitly — the pattern where total T reads normal but visceral adiposity, low SHBG (sex hormone binding globulin — the protein that keeps testosterone unavailable in circulation), and elevated estradiol from peripheral aromatization unmask a functional androgen insufficiency. It's real, it's common, and it's easy to miss if you only look at total T. But none of the markers fit here: minimal subcutaneous adiposity, normal SHBG, no estradiol elevation, no prediabetic picture driving insulin-mediated SHBG suppression. Would have tipped: SHBG below 20, estradiol elevated, central adiposity pattern, insulin resistance.

Obesity-driven inflammation. Not obese. CRP unremarkable — not even a whisper of the low-grade inflammatory signal that rides alongside visceral fat accumulation. Would have tipped: hs-CRP meaningfully elevated, central adiposity, ApoB climbing.

Metabolic disarray. HbA1c excellent. Fasting insulin in range. Lipids fine. No insulin resistance, no atherogenic dyslipidemia, no prediabetic trajectory to explain energy dysregulation. Would have tipped: A1c at threshold, HOMA-IR elevated, lipid pattern shifting unfavorably.

Thyroid. Screened. TSH and free T3 in range. Worth checking in this phenotype; rarely the answer when everything else is this clean.

What's left is the diagnosis no panel was going to find — because no panel measures it.

One level lower

The 40s are when mitochondrial efficiency starts to fall. Not dramatically, not all at once — but measurably, and ahead of any hormone panel finding. NAD+, the coenzyme the electron transport chain runs on and the fuel for sirtuin-mediated cellular repair, drops 40–60% between ages 40 and 70. The driver is rising CD38 ectoenzyme activity on immune cells, which consumes NAD+ as part of inflammatory signaling. It's not a disease process. It's a calendar process.

At the same time, the organized arrangements of protein complexes that turn electron flow into ATP — the ETC supercomplexes — become less efficient as their scaffold degrades. That scaffold is cardiolipin, a unique phospholipid on the inner mitochondrial membrane that holds the ETC together physically. Cardiolipin is sensitive to oxidative stress. When it breaks down, electron transfer becomes inefficient, ROS generation goes up, and ATP output per unit of substrate drops. The machinery is running, just not at the efficiency it used to.

These changes don't show on a standard panel. No standard panel measures them. The signal is the gap between effort and result — which is exactly what this patient was describing.

The decision

We layered SS-31 and NAD+ onto the existing recovery stack we'd been running for tendons (BPC-157 and TB-4). SS-31 — elamipretide — is a cardiolipin-targeted tetrapeptide that stabilizes ETC supercomplexes in dysfunctional mitochondria. It concentrates more than 1,000-fold in mitochondrial membranes. Importantly, it has no measurable effect on healthy mitochondria — its benefit scales with existing dysfunction. The human evidence anchor is FDA accelerated approval in Barth syndrome, a genetic cardiolipin deficiency disease, with ongoing trials in heart failure and AMD. NAD+ injectable replenishes the coenzyme pool the age-related CD38 rise has been depleting.

Dosing: SS-31 10 mg SubQ daily, 5×/week. NAD+ 100 mg SubQ 2×/week. Oral mito foundation running continuously: Urolithin A for mitophagy, CoQ10 as ETC electron carrier, PQQ to support mitochondrial biogenesis, Magnesium Glycinate 400 mg as ATP-synthesis cofactor. All injectable peptides are prescription compounds, evaluated and dosed under physician supervision, sourced through a 503A-licensed compounding pharmacy, and available in select states. Not a definitive answer — an addition motivated by the absence of one.

What happened

Within roughly a week, the subjective signal shifted. Workouts felt more productive. Recovery shortened. We want to be honest about what that is: subjective, early, and properly caveated. Lab follow-up at week 8 will give us objective data. The data is early. We're watching, not concluding.

Next issue, the molecules — what NAD+, MOTS-c, and SS-31 actually do at the cell. After that, why we add them in a sequence rather than all at once — and what the order changes.

If your last panel came back reassuring and your recovery still isn't — bring it up. That gap is itself a finding.

Kinetic Edge Health is a physician-led telehealth practice focused on longevity, metabolic optimization, and urological wellness. If a stack in this issue is relevant to you, book a strategy session.

Short-form dispatches on longevity, metabolic health, and men’s performance — from the founder of Kinetic Edge Health.

Telehealth practice. Prescription compounds and peptides require physician evaluation. Not available in all states.

kineticedgehealth.com · Cleveland, OH

© 2026 Kinetic Edge Health, Inc. · All rights reserved.

Not for you anymore?

Use the unsubscribe link below to stop future issues.